Vimarsana
Biggest News Aggregation in the World

Page 24 - Linical Studies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Linical Studies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Linical Studies Today - Breaking & Trending Today

US Senate Confirms Monica Bertagnolli as NIH Director - Vimarsana News

US Senate Confirms Monica Bertagnolli as NIH Director

The US Senate on Tuesday voted to confirm President Joe Biden's pick to run the National Institutes of Health, Monica Bertagnolli.

Standing BP Measures Improve Hypertension Diagnosis - Vimarsana News

Standing BP Measures Improve Hypertension Diagnosis

Adding blood pressure measurements while a patient is standing increases the sensitivity to detect hypertension, a new study suggests.

Crinetics Pharmaceuticals Inc (CRNX) Reports Q3 2023 Results: Phase 3 Success and Financial Growth - Vimarsana News

Crinetics Pharmaceuticals Inc (CRNX) Reports Q3 2023 Results: Phase 3 Success and Financial Growth

Key Developments and Financial Performance for Third Quarter 2023

Source: yahoo.com
Humacyte Third Quarter 2023 Financial Results and Business Update - Vimarsana News

Humacyte Third Quarter 2023 Financial Results and Business Update

– Positive top line results from the V005 Phase 2/3 trial of the Human Acellular Vessel™ (HAV™) in vascular trauma repair – – BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter – - Conference call and live webcast at 4:30 p.m. ET today - DURHAM, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, t

Source: yahoo.com
No Harm in Short Aspirin Duration After PCI for ACS - Vimarsana News

No Harm in Short Aspirin Duration After PCI for ACS

Less than a month of ticagrelor plus aspirin therapy followed by ticagrelor alone for 1 year after PCI for ACS was noninferior to dual antiplatelet therapy in the T-PASS trial.